Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 9/20 | 0.42 |
| ▸ | KDM5A | P29375 | 7/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 5/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 5/20 | 0.39 |
| ▸ | KDM4A | O75164 | 4/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869961 | 0.90 | PIK3CA (0.51) | PIK3CAPROKR1DPP4 | |
| SCHEMBL4764944 | 0.82 | SCD (0.33) | SCD | |
| SCHEMBL4880729 | 0.76 | PTGER1 (0.39) | — | |
| SCHEMBL4868563 | 0.74 | ABCC2 (0.45) | — | |
| SCHEMBL4876224 | 0.74 | PIK3CA (0.42) | PIK3CAKDM4CKDM5AKDM2BKDM5B | |
| SCHEMBL4874945 | 0.73 | ITGAL (0.38) | — | |
| SCHEMBL3738805 | 0.69 | PIK3CA (0.65) | PIK3CAKDM4CKDM5AKDM2BKDM5B | |
| SCHEMBL16966428 | 0.69 | PIK3CA (0.65) | PIK3CAKDM4CKDM5AKDM2BKDM5B | |
| SCHEMBL12552657 | 0.69 | PIK3CA (0.60) | PIK3CAKDM4CKDM5AKDM2BKDM5B | |
| SCHEMBL3743262 | 0.68 | PIK3CA (0.67) | PIK3CAKDM4CKDM5AKDM2BKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312211-A1 | Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | claimed |
| EP-1991545-A2 | ANTIBACTERIAL PYRROLOPYRIDINES, PYRROLOPYRIMIDINES, AND PYRROLOAZEPINES | AstraZeneca AB (SE) | 2008-11-19 | — | — | EP | claimed |
| WO-2007071965-A2 | ANTIBACTERIAL PYRROLOPYRIDINES, PYRROLOPYRIMIDINES, AND PYRROLOAZEPINES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312211-A1 | Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154 | SDHA, QDPR, PNKP | PIK3CA 494/4885KDM4C 2021/4885KDM5A 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.